The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.
 
Fumito Ito
No Relationships to Disclose
 
Shelly Bian
No Relationships to Disclose
 
Andrew S. Lim
No Relationships to Disclose
 
Priya Jayachandran
No Relationships to Disclose
 
Danielle R. Sterrenberg
No Relationships to Disclose
 
Evanthia T. Roussos Torres
No Relationships to Disclose
 
William Dean Wallace
No Relationships to Disclose
 
Rowena O. Vergara
No Relationships to Disclose
 
Azadeh A. Carr
No Relationships to Disclose
 
Emily L. Siegel
No Relationships to Disclose
 
Amanda M. Woodworth
No Relationships to Disclose
 
Stella Yoo
No Relationships to Disclose
 
Maria E. Nelson
No Relationships to Disclose
 
Stephen Francis Sener
No Relationships to Disclose
 
Diane C. Ling
No Relationships to Disclose
 
Daphne B. Stewart
No Relationships to Disclose
 
Darcy V. Spicer
No Relationships to Disclose
 
James S Hu
No Relationships to Disclose
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Jason C. Ye
No Relationships to Disclose